Literature DB >> 29661828

Nasopharyngeal Exposure to Streptococcus pneumoniae Induces Extended Age-Dependent Protection against Pulmonary Infection Mediated by Antibodies and CD138+ Cells.

Elsa N Bou Ghanem1, Nang H Tin Maung2, Nalat Siwapornchai3, Aaron E Goodwin2, Stacie Clark3,4, Ernesto J Muñoz-Elías5, Andrew Camilli3,6, Rachel M Gerstein2, John M Leong7.   

Abstract

Streptococcus pneumoniae commonly resides asymptomatically in the nasopharyngeal (NP) cavity of healthy individuals but can cause life-threatening pulmonary and systemic infections, particularly in the elderly. NP colonization results in a robust immune response that protects against invasive infections. However, the duration, mechanism, and cellular component of such responses are poorly understood. In this study, we found that repeated NP exposure of mice to S. pneumoniae TIGR4 strain results in pneumococcal-specific Ab responses that protect against lethal lung challenge. Abs were necessary and sufficient for protection because Ab-deficient μMT mice did not develop postexposure protection, only becoming resistant to lung infection after transfer of immune sera from NP-exposed mice. T cells contributed to immunity at the time of NP exposure, but neither CD4+ nor CD8+ T cells were required. The protective activity was detectable 20 wk after exposure and was maintained in irradiated mice, suggesting involvement of long-lived Ab-secreting cells (ASC), which are radioresistant and secrete Abs for extended periods of time in the absence of T cells or persistent Ag. CD138+ bone marrow cells, likely corresponding to long-lived ASC, were sufficient to confer protection. NP exposure of aged mice failed to protect against subsequent lung infection despite eliciting a robust Ab response. Furthermore, transfer of CD138+ bone marrow cells or sera from NP-exposed old mice failed to protect naive young mice. These findings suggest that NP exposure elicits extended protection against pneumococcal lung infection by generating long-lived CD138+ ASC and that the protective efficacy of these responses declines with age.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Year:  2018        PMID: 29661828      PMCID: PMC6047064          DOI: 10.4049/jimmunol.1701065

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  63 in total

1.  Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci.

Authors:  R Malley; M Lipsitch; A Stack; R Saladino; G Fleisher; S Pelton; C Thompson; D Briles; P Anderson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche.

Authors:  Stéphane Chevrier; Céline Genton; Axel Kallies; Alexander Karnowski; Luc A Otten; Bernard Malissen; Marie Malissen; Marina Botto; Lynn M Corcoran; Stephen L Nutt; Hans Acha-Orbea
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

3.  Complete genome sequence of a virulent isolate of Streptococcus pneumoniae.

Authors:  H Tettelin; K E Nelson; I T Paulsen; J A Eisen; T D Read; S Peterson; J Heidelberg; R T DeBoy; D H Haft; R J Dodson; A S Durkin; M Gwinn; J F Kolonay; W C Nelson; J D Peterson; L A Umayam; O White; S L Salzberg; M R Lewis; D Radune; E Holtzapple; H Khouri; A M Wolf; T R Utterback; C L Hansen; L A McDonald; T V Feldblyum; S Angiuoli; T Dickinson; E K Hickey; I E Holt; B J Loftus; F Yang; H O Smith; J C Venter; B A Dougherty; D A Morrison; S K Hollingshead; C M Fraser
Journal:  Science       Date:  2001-07-20       Impact factor: 47.728

4.  Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model.

Authors:  Krzysztof Trzcinski; Claudette Thompson; Richard Malley; Marc Lipsitch
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells.

Authors:  Morgan Taillardet; Ghina Haffar; Paul Mondière; Marie-Jeanne Asensio; Hanane Gheit; Nicolas Burdin; Thierry Defrance; Laurent Genestier
Journal:  Blood       Date:  2009-09-18       Impact factor: 22.113

6.  Impaired innate mucosal immunity in aged mice permits prolonged Streptococcus pneumoniae colonization.

Authors:  Cassandra L Krone; Krzysztof Trzciński; Tomasz Zborowski; Elisabeth A M Sanders; Debby Bogaert
Journal:  Infect Immun       Date:  2013-09-30       Impact factor: 3.441

Review 7.  A distinct role for B1b lymphocytes in T cell-independent immunity.

Authors:  K R Alugupalli
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

8.  Protective contributions against invasive Streptococcus pneumoniae pneumonia of antibody and Th17-cell responses to nasopharyngeal colonisation.

Authors:  Jonathan M Cohen; Suneeta Khandavilli; Emilie Camberlein; Catherine Hyams; Helen E Baxendale; Jeremy S Brown
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

9.  Human nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage.

Authors:  Adam K A Wright; Daniela M Ferreira; Jenna F Gritzfeld; Angela D Wright; Kathryn Armitage; Kondwani C Jambo; Emily Bate; Sherouk El Batrawy; Andrea Collins; Stephen B Gordon
Journal:  PLoS Pathog       Date:  2012-04-05       Impact factor: 6.823

10.  Pneumococcal conjugate vaccine for adults: a new paradigm.

Authors:  Peter R Paradiso
Journal:  Clin Infect Dis       Date:  2012-04-11       Impact factor: 9.079

View more
  8 in total

1.  Testing Anti-Pneumococcal Antibody Function Using Bacteria and Primary Neutrophils.

Authors:  Manmeet Bhalla; Shaunna R Simmons; Essi Y I Tchalla; Elsa N Bou Ghanem
Journal:  Methods Mol Biol       Date:  2021

2.  Neutrophils Are Required During Immunization With the Pneumococcal Conjugate Vaccine for Protective Antibody Responses and Host Defense Against Infection.

Authors:  Essi Y I Tchalla; Manmeet Bhalla; Elizabeth A Wohlfert; Elsa N Bou Ghanem
Journal:  J Infect Dis       Date:  2020-09-14       Impact factor: 5.226

3.  A Murine Model for Enhancement of Streptococcus pneumoniae Pathogenicity upon Viral Infection and Advanced Age.

Authors:  Basma H Joma; Nalat Siwapornchai; Vijay K Vanguri; Anishma Shrestha; Sara E Roggensack; Bruce A Davidson; Albert K Tai; Anders P Hakansson; Simin N Meydani; John M Leong; Elsa N Bou Ghanem
Journal:  Infect Immun       Date:  2021-07-15       Impact factor: 3.441

Review 4.  Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease.

Authors:  William Walkowski; Justin Bassett; Manmeet Bhalla; Blaine A Pfeifer; Elsa N Bou Ghanem
Journal:  Vaccines (Basel)       Date:  2021-06-02

Review 5.  Mechanisms of Naturally Acquired Immunity to Streptococcus pneumoniae.

Authors:  Elisa Ramos-Sevillano; Giuseppe Ercoli; Jeremy S Brown
Journal:  Front Immunol       Date:  2019-03-01       Impact factor: 7.561

6.  The Age-Driven Decline in Neutrophil Function Contributes to the Reduced Efficacy of the Pneumococcal Conjugate Vaccine in Old Hosts.

Authors:  Shaunna R Simmons; Essi Y I Tchalla; Manmeet Bhalla; Elsa N Bou Ghanem
Journal:  Front Cell Infect Microbiol       Date:  2022-03-23       Impact factor: 6.073

7.  Liposomal Encapsulation of Polysaccharides (LEPS) as an Effective Vaccine Strategy to Protect Aged Hosts Against S. pneumoniae Infection.

Authors:  Manmeet Bhalla; Roozbeh Nayerhoda; Essi Y I Tchalla; Alexsandra Abamonte; Dongwon Park; Shaunna R Simmons; Blaine A Pfeifer; Elsa N Bou Ghanem
Journal:  Front Aging       Date:  2021-12-22

8.  Lung-resident memory B cells protect against bacterial pneumonia.

Authors:  Kimberly A Barker; Neelou S Etesami; Anukul T Shenoy; Emad I Arafa; Carolina Lyon de Ana; Nicole Ms Smith; Ian Mc Martin; Wesley N Goltry; Alexander Ms Barron; Jeffrey L Browning; Hasmeena Kathuria; Anna C Belkina; Antoine Guillon; Xuemei Zhong; Nicholas A Crossland; Matthew R Jones; Lee J Quinton; Joseph P Mizgerd
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.